A 30-year mystery of how the molecular machinery works through an enzyme that makes a potent antibiotic was revealed by the scientists at Rutgers and universities in Russia, Poland, and England.
The findings, which appear in the journal Molecular Cell, provide the tools to design new antibiotics, anticancer drugs and other therapeutics.
Antibiotics
Antibiotics are among the most used and abused medications. This article explains some general features about antibiotics.
Advertisement
‘Enzyme machines like McbBCD as a production tool could help develop potent new antibiotics and anticancer drugs.’
Read More..
Tweet it Now
Read More..
The potent natural antibiotic, microcin B17, kills harmful E. coli bacteria. Microbial resistance to antibiotics- due to their overuse and misuse - is one of the biggest threats facing humanity, and there's an urgent need to find new drugs. Natural antibiotics that evolved over eons represent an attractive option to overcome resistance.
The scientists studied a molecular machine: an enzyme (protein) called McbBCD. The enzyme makes microcin B17 from a smaller protein known as a peptide. Scientists have known about microcin B17 and its unusual chemical structure for decades, but they did not understand the molecular machinery that makes it until now.
The scientists found that the enzyme triggers two chemical reactions that produce several chemical "cycles" required for antibacterial activity, according to senior author Konstantin Severinov, a principal investigator at the Waksman Institute of Microbiology and professor of molecular biology and biochemistry at Rutgers University-New Brunswick.
"Our research allows rational design of new peptide compounds that could become treatments ranging from antimicrobials to anticancer drugs," Severinov said. "There may be a trove of new antibiotics that could be made from peptides, using enzyme machines like McbBCD as a production tool."
The international team included scientists at the Skolkovo Institute of Science and Technology in Russia; Russian Academy of Sciences in Russia; Jagiellonian University in Poland; John Innes Centre in England; and Lomonosov Moscow State University in Russia.
Source: Eurekalert
Advertisement
The scientists found that the enzyme triggers two chemical reactions that produce several chemical "cycles" required for antibacterial activity, according to senior author Konstantin Severinov, a principal investigator at the Waksman Institute of Microbiology and professor of molecular biology and biochemistry at Rutgers University-New Brunswick.
"Our research allows rational design of new peptide compounds that could become treatments ranging from antimicrobials to anticancer drugs," Severinov said. "There may be a trove of new antibiotics that could be made from peptides, using enzyme machines like McbBCD as a production tool."
The international team included scientists at the Skolkovo Institute of Science and Technology in Russia; Russian Academy of Sciences in Russia; Jagiellonian University in Poland; John Innes Centre in England; and Lomonosov Moscow State University in Russia.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial